China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of China Traditional Chinese Medicine Holdings Co. Limited $0.21, price $0.16, upside +28.8%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch China Traditional Chinese Medicine Holdings Co. Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
59‑month range $0.1631 – $0.5079 · fair‑value band $0.1700 – $0.2500 · the $0.1631 price screens below the $0.2100 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow China Traditional Chinese Medicine Holdings Co. in your weekly email
Every Wednesday you see whether China Traditional Chinese Medicine Holdings Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally.
Show more
China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM therapies, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical products; investment of the TCM health industry; sale of medical herbs; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong.
Stock analysis
China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) currently trades at $0.1631, while our model-based Fair Value estimate is $0.2100, implying the stock looks roughly 22.3% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $0.8300 per share, and 14 of the 16 models we run sit above the $0.1631 price.
Bear case: the Dividend Discount group reads lowest at $0.1500, and 2 of the 16 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.1700 (bear) to $0.2500 (bull), the price of $0.1631 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
China Traditional Chinese Medicine Holdings Co. Limited reported revenue of 14.4B CNY in FY2025 versus 19.1B CNY in FY2021, a compound −6.8%/yr. Reported net income was −333M CNY in FY2025.
Key figures
Market cap $1.1B · P/S ratio 0.07 · EPS (TTM) $−0.0100 · Net margin −2.3% · Return on equity −2.0% · Return on assets (EBIT) 3.3% · Operating margin 3.6% · Revenue (TTM) 14.7B CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 53% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 29%, CHIZF screens cheaper than that median.
Fair Value models
Bear $0.1700Fair Value $0.2100Bull $0.2500
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.9%
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.8% (2020) → 2.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−39.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −40.3% a year for the price.
Compare China Traditional Chinese Medicine Holdings Co. Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 624 stocks
Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside+28.8% · Top 25%
Profitability
Return on assets0.8% · Below median
Net margin (TTM)−2.3% · Below median
Operating margin (TTM)3.6% · Below median
Growth and dividend
Revenue growth−10.4% · Bottom 25%
Balance sheet
Debt / equity0.01× · Lowest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "China Traditional Chinese Medicine Holdings Co. Limited Fair Value". https://www.fairvalue-calculator.com/stock/CHIZF
Frequently asked questions
Is China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.2100 versus a price of $0.1631, about +29% upside (undervalued).
What is the fair value of CHIZF?
Our model-based fair value for China Traditional Chinese Medicine Holdings Co. Limited is $0.2100 (as of Sep 24, 2026), built from audited fundamentals. The current price: $0.1631.
What is the quality score of CHIZF?
China Traditional Chinese Medicine Holdings Co. Limited has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for China Traditional Chinese Medicine Holdings Co. Limited (CHIZF)?
Our model-based price target is the fair value of $0.2100 (as of Sep 24, 2026) from 16 valuation models. Cautious scenario $0.1700, optimistic scenario $0.2500. It is a calculation from audited fundamentals, not an analyst target.
What is the China Traditional Chinese Medicine Holdings Co. Limited stock forecast for 2026?
Our models put fair value at $0.2100, about +29% upside versus a price of $0.1631 (undervalued). Cautious scenario $0.1700, optimistic scenario $0.2500. The calculation is refreshed regularly with new filings.
What is the revenue of China Traditional Chinese Medicine Holdings Co. Limited (CHIZF)?
China Traditional Chinese Medicine Holdings Co. Limited reported trailing-twelve-month revenue of about 14.7B CNY (latest available figure, as of Sep 24, 2026).
What growth is priced into China Traditional Chinese Medicine Holdings Co. Limited (CHIZF)?
For today's price to be fair in a discounted-cash-flow model, China Traditional Chinese Medicine Holdings Co. Limited would have to grow free cash flow by -39.3 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.6 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of CHIZF use?
Our models discount China Traditional Chinese Medicine Holdings Co. Limited at 10.4 %: a base by market capitalisation (small), damped by beta 0.71, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For China Traditional Chinese Medicine Holdings Co. Limited that is -39.3 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) delivered so far?
Over the past 5 years revenue at China Traditional Chinese Medicine Holdings Co. Limited grew -0.6 % a year. The price currently implies -39.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into China Traditional Chinese Medicine Holdings Co. Limited (-39.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of China Traditional Chinese Medicine Holdings Co. Limited (CHIZF)?
The free-cash-flow yield on the price is 35.54 %: that much free cash flow China Traditional Chinese Medicine Holdings Co. Limited produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of China Traditional Chinese Medicine Holdings Co. Limited (CHIZF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For China Traditional Chinese Medicine Holdings Co. Limited it is $0.2100 per share (as of Sep 24, 2026), against a price of $0.1631. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is China Traditional Chinese Medicine Holdings Co. Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, CHIZF trades below its calculated fair value: price $0.1631, fair value $0.2100, a gap of about +29% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CHIZF?
No. The price is what the market pays today ($0.1631); the fair value is what the company's own numbers justify ($0.2100). For China Traditional Chinese Medicine Holdings Co. Limited the two are $0.0469 per share apart. That gap is exactly why we show both numbers side by side.
How much is China Traditional Chinese Medicine Holdings Co. Limited worth?
The market values China Traditional Chinese Medicine Holdings Co. Limited at about $1.1B (market capitalisation, as of Sep 24, 2026). Per share that is $0.1631; our models calculate a fair value of $0.2100 per share.
What do the bullish and bearish scenarios say about CHIZF?
Our models span a range for China Traditional Chinese Medicine Holdings Co. Limited: cautious scenario $0.1700, base $0.2100, optimistic $0.2500 per share (as of Sep 24, 2026, price $0.1631). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of China Traditional Chinese Medicine Holdings Co. Limited (CHIZF)?
Balance-sheet figures for China Traditional Chinese Medicine Holdings Co. Limited (as of Sep 24, 2026): return on equity −2.0%, debt of 0.01 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is CHIZF from its 52-week high?
China Traditional Chinese Medicine Holdings Co. Limited trades at $0.1631, about 53% below its 52-week high of $0.3454 and at the low of $0.1631 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2100 is for.
Which stocks are comparable to China Traditional Chinese Medicine Holdings Co. Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is China Traditional Chinese Medicine Holdings Co. Limited stock attractive at the current price?
The data as of Sep 24, 2026: price $0.1631, calculated fair value $0.2100 (+29%), Quality Score 55/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CHIZF calculated?
We run China Traditional Chinese Medicine Holdings Co. Limited through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.2100, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. China Traditional Chinese Medicine Holdings Co. Limited currently trades 22 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of China Traditional Chinese Medicine Holdings Co. Limited (CHIZF)?
The closing price on Sep 25, 2026 was $0.1631. Our model-based fair value is $0.2100, about +29% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with China Traditional Chinese Medicine Holdings Co. Limited right now?
The price is below even our cautious bear case ($0.1700). The market is more pessimistic than our downside scenario. Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) come from?
Earnings per share at China Traditional Chinese Medicine Holdings Co. Limited grew −4.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +13.1 %, EBIT margin −15.4 %, tax rate +2.5 %, residual (interest, one-offs) −2.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of China Traditional Chinese Medicine Holdings Co. Limited
How large is the market capitalisation of China Traditional Chinese Medicine Holdings Co. Limited (CHIZF)?
The market capitalisation of China Traditional Chinese Medicine Holdings Co. Limited is $1.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of China Traditional Chinese Medicine Holdings Co. Limited (CHIZF)?
The price-to-sales ratio of China Traditional Chinese Medicine Holdings Co. Limited is 0.07 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of China Traditional Chinese Medicine Holdings Co. Limited (CHIZF)?
Earnings per share at China Traditional Chinese Medicine Holdings Co. Limited are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of China Traditional Chinese Medicine Holdings Co. Limited (CHIZF)?
The net margin of China Traditional Chinese Medicine Holdings Co. Limited is −2.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of China Traditional Chinese Medicine Holdings Co. Limited (CHIZF)?
The return on equity (ROE) of China Traditional Chinese Medicine Holdings Co. Limited is −2.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of China Traditional Chinese Medicine Holdings Co. Limited (CHIZF)?
On an EBIT basis the return on assets of China Traditional Chinese Medicine Holdings Co. Limited is 3.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of China Traditional Chinese Medicine Holdings Co. Limited (CHIZF)?
The operating margin of China Traditional Chinese Medicine Holdings Co. Limited is 3.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at China Traditional Chinese Medicine Holdings Co. Limited (CHIZF)?
Revenue at China Traditional Chinese Medicine Holdings Co. Limited is growing −10.4% versus a year earlier (3y avg +0.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at China Traditional Chinese Medicine Holdings Co. Limited (CHIZF)?
Earnings per share at China Traditional Chinese Medicine Holdings Co. Limited are growing −63.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) hold?
China Traditional Chinese Medicine Holdings Co. Limited holds more cash than debt, 1.6B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch China Traditional Chinese Medicine Holdings Co. Limited in the live analysis
One click puts China Traditional Chinese Medicine Holdings Co. Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026